Daycase Hip and Knee Arthroplasty in Møre and Romsdal Trial
Key facts
- Who runs it
- Helse Møre og Romsdal HF
- Where
- Norway3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 300 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 31 Jul 2036
- Type of study
- Observational, 3 groups
- Treatments tested
- Total Hip Arthroplasty
- Total Knee Arthroplasty
- Unicondylar knee artrhoplasty
- Record updated
- 22 September 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients 18-80 years old scheduled for primary TKA, UKA or THA
Who cannot take part
- Patient not motivated for daycase surgery, lack of adult caregiver staying with the patient for the first 24 hours post-discharge, ASA class 3 (if not approved by anesthesiologist) and 4, travel distance to acute hospital no more than 1 hour (ferry-free), dementia or other reasons for lacking compliance (e.g. substance abuse, severe psychiatric disorder etc.) BMI >40 kg/m2, patients with anticipated high level of pain due to previous experience, comorbidity (i.e. chronic pain syndrome, fibromyalgia), patients treated with opoid analgesics on a regular basis prior to surgery
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The DART Study is a prospective, multicentre observational cohort study evaluating day-case pathways for patients undergoing primary total hip arthroplasty, total knee arthroplasty, or unicompartmental knee arthroplasty at three hospitals in Møre og Romsdal, Norway (Volda, Ålesund and SNR). All patients scheduled for these procedures will be screened for eligibility for same-day discharge using predefined clinical, functional, and logistical criteria.
Read full original descriptionShow less
The primary objective is to determine the proportion of patients who are discharged on the day of surgery. Secondary objectives are to assess recovery, pain, complications, emergency department visits, readmissions, reoperations, and mortality during the first 30 days after surgery. Patient-reported outcomes, including quality of recovery, joint-specific function, quality of life, pain, and awareness of the joint replacement, will be assessed before surgery and during follow-up for up to three months.
Clinical and patient-reported data will be collected prospectively. Outcomes for patients discharged on the day of surgery will be compared with those of patients who remain in hospital overnight or longer. The study aims to evaluate the feasibility, safety, and patient experience of implementing standardized day-case hip and knee arthroplasty pathways within routine clinical practice.
The 3 groups in the trial
- Total Hip Arthroplasty
Eligable patients for daycase surgery with hip osteoarthritis, osteonecrosis or other indication for total hip arthroplasty
- Total Knee Arthroplasty
Eligable patients for daycase surgery with knee osteoarthritis, osteonecrosis or other indication for total knee arthroplasty
- Unicondylar Knee Arthroplasty
Eligable patients for daycase surgery with knee osteoarthritis, osteonecrosis or other indication for unicondylar knee arthroplasty
Treatment: Unicondylar knee artrhoplasty
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT07834034, who can take part
- Record updated
- 22 September 2026